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Nutrition  has  a  predominant  and  recognizable  role  in  health  management.  Nutrigenetics
is  the  science  that identiﬁes  and  characterizes  gene  variants  associated  with  differential
response  to nutrients  and  relating  this  variation  to variable  disease  states  especially  cancer.
This arises  from  the  epidemiological  fact that  cancer  accounts  for a high  proportion  of  total
morbidity  and  mortality  in  adults  throughout  the  world.  There  is  much  evidence  to support
that genetic  factors  play  a key role  in the development  of  cancer;  these  genetic  factors  such
as  DNA  instability  and  gene  alterations  are  affected  by nutrition.  Nutrition  may  also  lead
to aberrant  DNA  methylation,  which  in  turn  contributes  to carcinogenesis. The  aim  of this
work is to clarify  the  basic  knowledge  about  the  vital  role  of  nutrition-related  genes  in
various  disease  states,  especially  cancer,  and  to identify  nutrigenetics  as a new  concept
that  could  highlight  the  relation  between  nutrition  and  gene  expression.  This  may  help  to
understand  the  mechanism  and  pathogenesis  of  cancer.  The  cause  of  cancer  is  a complex
interplay  mechanism  of genetic  and  environmental  factors.  Dietary  nutrient  intake  is  an
essential environmental  factor  and  there  is a marked  variation  in  cancer  development  with
the same  dietary  intake  between  individuals.  This  could  be explained  by  the  variation  in
their  genetic  polymorphisms,  which  leads  to emergence  of  the  concept  of nutrigenomics
and  nutrigenetics.
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1. Nutrigenetics
1.1. Nutrition and health equation
It is an old fact that diet affects health. Hippocrates
advised physicians in 400 BC: “Leave your drugs in the
chemist’s pot if you can heal your patient with food.” Fur-
thermore, it is well known that humans differ in their
demands for particular nutrients [1].
Nutrition can contribute to disease pathogenesis or
appearance either directly or indirectly. Nutrients and
foods usually interact with genes in a benign manner, but
sometimes this interaction can have fatal outcomes [2].
Humans are affected by both environmental and genetic
factors; both factors must be considered equally to main-
tain normal health condition of the individual. Previous
studies were mostly directed either to the effect of envi-
ronmental factors alone or to genes only but not to both
together. Recently, research has been designed to study
gene–nutrition interaction [3].
Nutrition science investigates how nutrients can main-
tain normal and stable body homeostasis at the level of
the cell, tissues, and organs. This science needs to under-
stand the mechanism of nutrient-dependent interactions
at the genetic molecular, protein production and metabolic
proﬁle levels [4,5]. Thus, nutrition research has proceeded
from epidemiological and physiological aspects to molec-
ular biology and genetics aspects as well as nutritional
genomics [6,7].
1.2. Nutrition and genes (diet–gene interaction)
1.2.1. Nutrition and genetic variation
The Human Genome Project offers great help to the sci-
ence of nutritional genomics. It helps scientists to discover
multiple mutual relations between genes, nutrition, and
diseases [8]. Sequencing of the human genome revealed
signiﬁcant genetic heterogeneity within human popula-
tions. Millions of single nucleotide polymorphisms (SNPs)
have been found to have a relation to nutrition [9].If SNPs are accommodated in the involved genes in
metabolism of drugs, environmental agents, or dietary
components, they may  highly affect the individual
response to exposure including diet [10]..  . .  .  . . . . . .  . . . . . . . . . . . . .  . . .  . . . . . . . .  . . .  . . . .  .  . .  . . .  . . . . . . . .  .  . . . .  .  .  . . . .121
1.2.2. Biological complexity of gene–diet interaction
The interaction between nutrition, metabolism, and
gene expression is mandatory for maintenance of body
homeostasis. Nutrition related or dependent disorders
have been reported to be the result of a mixture of
nutrients with multiple genes not with a single gene
[11,12]. Genetic variation is the major basis for person-to-
person divergence in response to diet. Understanding how
genetic variation inﬂuences gene expression and recog-
nizing genetic variants as risk factors for human nutrition
dependent or related disorders is the focus of nutrigenetics
[13].
1.2.2.1. Nutritional genomics (nutrigenomics and nutrigenet-
ics). There is an interacting two-way relationship between
nutrition and the human genome. It deﬁnes and marks
the gene expression and metabolic response. Then, it may
affect the individual’s health condition and susceptibility
to disease [14]. Firstly, the genetic background of the indi-
vidual can deﬁne the nutrient state, metabolic response,
and susceptibility to diet-dependent or related health dis-
orders [10]. Secondly, nutrients regulate the transcription
factors that modify the gene expression, up or down, con-
sequently, adjust the metabolic responses at the molecular
level. The reason and result interplay between nutrition
and the human genome has led to production of new sub-
deﬁnitions, nutrigenetics, and nutrigenomics [7].
It is suggested that the science of nutrigenetics is
involved in handling the mechanism by which genetic vari-
ations deﬁne the risk of individual to diseases, nutrient
daily requirements, cellular metabolic response and behav-
ior towards the bioactive dietary components or nutritional
therapy, the main target of that is to clarify the impact of the
gene variability on the interaction between nutrients and
diseases. Nutrigenomics science is directed to review and
study the genome-broad impact of nutrition. It is interested
in the functional effect of various food components on the (-
omes) branch of science including genome, transcriptome,
proteome, and metabolome [14].
Nutrigenomics and nutrigenetics explore the interac-
tion between nutrients and genes. However, they are
clearly distinguished through the mechanisms of inter-
actions between nutrients and genes that determine
the risk of development of diseases. Nutrigenomics also
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haracterizes the impact of all aspects of nutrients as
ood-based, dietary limitation, or nutritional supplemen-
ary agents, on the gene expression. This will direct the
nterest to the genome-wide effects of nutrients on trans-
riptome, proteome, and metabolome in cells, tissues, or
rganisms. Moreover, it will characterize and conﬁrm the
enes that can inﬂuence the risk of diet-dependent dis-
ases. It may  also be useful in understanding how nutrients
an affect the metabolic pathways and how these regula-
ions can be inhibited in the early phase of diet-related and
iet-dependent diseases [15].
Dolinoy and Jirtle [16] proposed the manner of gene
xpression, protein expression, and metabolite production
s a result of exposure to nutrient and represented it by
ietary signature. Therefore, nutrigenomics also aims to
nderstand how these dietary signatures have an impact
n the cellular function and the balance of the internal
nvironment tissues within the whole body.
Principles of nutritional genomics
There are four principles of nutritional genomics [10].
(1) Diet is considered be a critical predisposing factor for
many diseases in some individuals under particular con-
ditions. (2) Diet ingredients change the gene structure
and/or gene expression, and consequently, the human
genome. (3) The variation of genotype between indi-
viduals can explain the equilibrium between health and
disease. (4) Genes that are dependent on dietary factors
in its regulation may  have a role in the commencement,
extent, advancement, and progression of chronic dis-
eases.
Examples of nutrigenomics
Dietary cholesterol performs an inhibitory effect on the
transcription -hydroxy--  methyl-glutaryl-CoA reduc-
tase gene. Dietary polyunsaturated fatty acids repress
mRNA production of fatty acid synthase in hepatocytes
through decreasing mRNA for lipogenic enzymes. This
process depends on the degree of unsaturation of fatty
acids [17].
Phenylketonuria is an example of single gene mutation.
Phenylketonuria patients should avoid phenylalanine-
rich food. Many Asian populations have the problem
of deﬁciency of the aldehyde dehydrogenase enzyme,
which is responsible for metabolism of ethanol. This leads
to an annoying manifestation in affected individuals after
ingestion of alcohol. Galactosemia is a disease that results
from an inherited genetic deﬁciency of one of the three
enzymes that are implicated in the metabolism of galac-
tose [18].
Examples of nutrigenetics
The methylenetetrahydrofolate reductase gene
(MTHFR) is a well-deﬁned example of a gene-nutrient
interaction. MTHFR is involved in the metabolism of
folic acid and maintenance of the normal blood level of
homocysteine. A particular MTHFR gene SNP is associ-
ated with elevated homocysteine levels of in the blood
of carriers, especially if there is a dietary deﬁciency of
folic acid [19].
Elevated homocysteine level is associated with car-
diovascular diseases, and an increased predisposition of
colon cancers, especially if there is also a marked dietary and Ultrastructure 4 (2016) 115–122 117
deﬁciency of folic acid compared to the recommended
daily requirement [10].
1.2.2.2. Nutritional epigenomics. Many studies in the ﬁeld
of epigenetics have concentrated on the hereditary vari-
ation of DNA and consequently protein production, and
how DNA and histones are linked, which could prompt
certain changes in the chromatin structure without any
change in the nucleotide sequence. Therefore alteration
in the process of gene expression can result from epige-
netic processing rather than change in DNA sequence such
as cytosine methylation of DNA and histone acetylation as
well as micro RNAs (miRNAs) and noncoding RNAs, which
are also implicated in the epigenetic setting and regula-
tion of the process of gene expression. Another study has
reported that miRNAs have a role in chromatin remodel-
ing: the mammalian genome carries the genetic code of
many types of miRNAs that adjust gene expression through
the modulating the mRNAs of interest [20]. These reported
results and facts propose that DNA methylation, histone
modiﬁcation, and miRNAs could play integrated roles to
regulate the process of gene expression [21].
Nutrients are involved in epigenetic changes that can
alter and modify the intracellular signaling pathways [22].
The ﬁrst concept concerning the role of dietary condition in
epigenetic changes and the mechanism by which these epi-
genetic changes have an effect on the health consequence
on long-dated amplitude were reported from the Dutch
Famine Cohort. Results from these cohort studies showed
that nutritional restriction during pregnancy could lead to
an increased rate of predisposition of metabolic disorders
in the progeny. The timing and the duration of maternal
starvation are signiﬁcant in determining the disease con-
sequences; the ﬁrst trimester of pregnancy showed more
liability to incidence of diseases during the early adulthood
stage. The results of the studies of the Dutch Famine Cohort
concluded two  important ﬁndings. First, there is a critical
time during the embryonic development at which dietary
behavior can stimulate and lead to epigenetic alterations;
second, these epigenetic modiﬁcations are deﬁnitely trans-
ferred to progeny [20].
2. Nutrient gene–cancer interaction
2.1. Foods and cancer (diet-related carcinogenesis)
Diet is a mix  of protective, carcinogenic, and mutagenic
agents; most of them are metabolized by the enzymes
of biotransformation process. Genetic polymorphisms that
change protein expression or the function of these enzymes
can modify the risk of developing cancer. More than 25,000
different bioactive food ingredients are proposed to be
present in the foods ingested by humans [23].
More than 500 types of these bioactive food ingredients
have been proved to be possible predisposing agents and
have a role in cancer pathogenesis and others are not. It is
thought that a diet containing protective micronutrients as
well as carcinogens and mutagens may  modulate the risk of
cancer development, especially in genetically susceptible
individuals [24].
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Table 1
Dietary components, polymorphic genes and cancer Quoted from (Panagiotakos et al. [25]).
Dietary component Polymorphic gene Cancer site
Carcinogens
Heterocyclic amines
(red & processed meat)
NAT-2, NAT-1, CYP1A2 Colorectal, breast, other sites
Polycyclic hydrocarbons
(red & processed meat)
CYP1A1, GSTM1 Gastrointestinal tract
Nitrosamines
(fried potatoes)
CYP2E1 Nasopharyngeal, stomach
Alcohol GSTM1, ADH (ALDH) Colorectal
Aﬂatoxins
(polluted grains)
CYP2E1 Liver
Anticarcinogens
Cruciferous vegetables CYP1A2, GST Colorectal, other sites
Fruits & vegetables CYP1A2, GST Many sites
Calcium/vitamin D Vitamin D receptor Colorectal, prostate
Retinoids Retinoic acid receptor Variant acute promylocytic Leukemia, skin, others
2; CYP2
rase 1,2.Folate, methionine MTHFR 
ADH (ALDH) = alcohol dehydrogenase; CYP1A2 = cytochrome P450 1A
methylene-tetrahydro-folate reductase; NAT-1, NAT-2 = N-acetyl transfe
These bioactive food ingredients may  emerge from
different sources such as plants (phytonutrients) and
animal sources (zoonutrients). These groups of dietary
components may  modulate the risk of cancer. They can
be classiﬁed according to their interaction with speciﬁc
genetic polymorphisms and how they affect each other
into carcinogenic and anticarcinogenic (protective) foods
[25]. Interactions between the different types of foods may
affect the overall response [26]. Some examples of these
two groups are presented in Table 1.
2.1.1. Molecular targets for bioactive food ingredients
Bioactive food ingredients and components function
to maintain normal cellular activity, affect the neoplas-
tic transition of normal cells to cancerous cells, and alter
the biological behavior and attitude of the neoplasm. It is
reported that these three states are important in modifying
the risk and behavior of cancer but the pathophysiological
mechanism is speciﬁc for each food type. Much evidence
indicates the role of each foods to adjust Phase I and Phase II
enzymes, which are xenobiotic metabolizing enzymes and
consequently conﬁrm maintenance of normal cells [27].
The modiﬁcation of metabolism of carcinogens is one
of the main possible mechanisms by which food compo-
nents can minimize the risk of cancer. The gene expression
of genes of the enzymes of Phase I xenobiotic metabolism,
which usually activate most of the carcinogens, is estab-
lished by xenobiotic sensing nuclear receptors such as AhR,
PXR, and RXR. Then, the enzymes of Phase II catalyze the
conjugations of these carcinogens and they are repeatedly
regulated by different signaling pathways at the level of
transcription [24].
The responses to dietary compounds that have a role
in preventing cancer may  be related to the diverse of the
enzymes being processed and modiﬁed. For example, gar-
lic is associated with autoactivation of CYP2E1, but does
not affect other CYP450 isozymes by the same mecha-
nism. Moreover, genetic polymorphisms in the regulatory
regions of the genes of metabolizing enzymes and trans-
porter proteins, such as AhR and PXR, may  affect the total
response to the bioactive food constituents [28].Colorectal, cervix
E1 = cytochrome P450 2E1; GST = glutathione-S-transferase; MTHFR =
Previous research [29–31] reported that many food
components can modify the neoplastic progression as well
as the programmed cell death (apoptosis). Key points in the
cell cycle are regulated by different protein kinase com-
plexes that are composed of cyclin and cyclin-dependent
kinase molecules. Also, these cell cycle key points are
affected by combined dietary components. It has been
proved that the dietary factors either essential or nonessen-
tial can adjust and modify the cell cycle checkpoints, and
consequently have a role in reducing the progression and
proliferation tumor [29].
Apigenin (celery, parsley), curcumin (turmeric),
epigallocatechin-3-gallate (green tea), resveratrol (red
grape, peanuts, and berries), genistein (soybean), and
allyl sulfur (garlic) have been reported to affect the cell
cycle by different mechanisms. Some of these changes
may  be associated with the processing of synthesized
proteins at the post-translational level. This modiﬁcation
includes shifts in the phosphorylation process of the main
regulatory factors of cell division [30].
Another mechanism postulated by which other food
ingredients can change the tumor behavior is by accel-
erating cell death and enhancing apoptosis. Apoptosis
occur through two known pathways: the intrinsic,
mitochondrial-mediated pathway; and the extrinsic, death
receptor-mediated pathway. Dietary components can
enhance or suppress the mechanism of apoptosis through
its effect on mRNA transcription or expression and function
of proteins. Some of these bioactive dietary components
may  also enhance apoptosis by stimulating free radical for-
mation of reactive oxygen/nitrogen species and production
in the cell [31].
2.1.2. Assessment of dietary intake
Precise and cheap methods for assessment of intake of
particular essential and the nonessential bioactive nutri-
ent components are essential to explore and resolve the
relationship between different individuals’ diet habits
and possibility of cancer development. Food frequency
questionnaires and 24-hour recall are considered to be
the major data collection tools for assessing dietary
roscopy and Ultrastructure 4 (2016) 115–122 119
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Table 2
Examples of genetic polymorphisms and related cancers Quoted from
(Lampe and Chang [39]).
Polymorphic gene Cancer
Cytochrome P450 Lung, breast, prostate, colon, liver, ovary
NAT2 Colon, bladder, breast
GSTs Head and neck, lung, prostate
MTHFR Colon
COMT Breast
XRCC1 Colon, skin, lung, head and neck
XPD Lung
COMT = catecholcatechol-O-methyltransferase; GSTs = glutathioneglu-
cinogenesis, such as those involved in DNA replication andA.Z. Elsamanoudy et al. / Journal of Mic
xposures, but they have some important limitations
24].
Absorption, metabolism, tissue distribution, and excre-
ion of these bioactive food ingredients can affect the
mount of these components that reach the target sites,
o it is mandatory to ﬁnd new methodologies that assess
hese variables and the effects at the cellular and molec-
lar levels [12]. Integrating the assessments of diet intake
ith the analyses of concentrations of these bioactive food
onstituents or metabolites (metabolomic proﬁle) in tis-
ues and/or body ﬂuids can provide special insights into
he individual responsiveness to food and the possible pro-
onged duration of dietary exposures [32].
.2. Factors affecting diet–gene–cancer interaction
.2.1. Genetic variation among individuals
Interindividual variability of the genome structure and
equences makes understanding gene–nutrient interac-
ions very complicated and difﬁcult. SNPs and copy number
ariations are the most predominant structural variations
n the human genome and consequently can partici-
ate in nutrient genetic heterogenecity [33]. For example,
hat variation in copy number of -amylase and many
ytochrome P450 genes has been reported. The increased
opy number variation of -amylase is related to a previous
istory of starchy food intake disorder [34].
.2.2. Epigenetics affects the response to diet
The term epigenetics refers to the constant changes in
NA structure without mutating its sequence but can alter
he expression of genetic information. The most commonly
escribed and characterized epigenetic mechanism is chro-
atin remodeling through histone modiﬁcation (and other
hromatin proteins) and DNA methylation [35].
Epigenetic alterations could perform an important role
uring the development and pathogenesis of different dis-
ase including cancer. It has been proved in many studies
hat genes that are responsible for cell cycle regulation,
NA repair, angiogenesis, and apoptosis are suppressed
nd inactivated by epigenetic modiﬁcation in the form of
ypermethylation of their speciﬁc own CpG islands [23,25].
The main categories of these regulatory genes that
re affected by DNA hypermethylation include the
umor suppressors cyclin dependent kinases, phosphatase,
nsulin-like growth factor-II, E-cadherin, and glutathione-
-transferase. DNA methylation patterns are proved to
e inﬂuenced by the intake of multiple and/or combined
ood ingredients as vitamin A and zinc; even nonessential
ietary components may  have a role [36].
In 2007, Fang et al. [35] demonstrated that methyl
eﬁcient diets could lead to an evident alteration in the
ethylation patterns observed in the process of transfor-
ation of normal cells to cancerous cells. It is reported that
enistein and related soy isoﬂavones through their possible
irect regulatory effect on DNA methyltransferase enzyme
an reactivate methylation-silenced genes. Genistein is a
hytoestrogenic compound of the isoﬂavone class that is
ound in plants and has a structure similar to estrogen
35].tathione-S-transferases; MTHFR = methylenetetrahydrofolate reductase;
NAT-2 = N-acetyl transferase-2; XPD: xeroderma pigmentosum gene
group D; XRCC1: X-ray cross-complementing group 1 protein.
There are complex events of reversible modiﬁcations
histone that could rule gene expression. These mecha-
nisms include reversible histone acetylation, change of
methylation pattern, phosphorylation/dephosphorylation,
ubiquitination, and biotinylation. Modiﬁcation of histone
deacetylase has been documented as an important mech-
anism for adjustment of tumor behavior [1].
Many other food ingredients including butyrate, diallyl
disulﬁde, and sulforaphane are considered to be weak lig-
ands for the enzyme histone deacetylase and lead to change
in its activity as observed in an in vitro study. Sulforaphane,
an isothiocyanate compound that is found in some antiox-
idant rich vegetables, may  lead to a marked increase in the
global and local histone acetylation state of the promoter
regions of the cellular senescence and proapoptotic genes,
P21, and bax genes [37].
2.2.3. Timing and quantity of exposure to diet
Choosing the time and duration of nutrient exposure
are important factors that determine the total response to
foods or other nutrients supplements. In an experimental
study, Virgili and Perozzi [38] concluded that the time of
exposure of rats to dietary genistein is a very important
factor in determining breast cancer risk.
2.3. Genes involved in cancer and interaction with diet
It is well known that humans show individual variability
in the vulnerability to carcinogenesis. Genetic polymor-
phisms play an important role and contribute to explain the
individual variation in cancer risk. Many studies have been
carried out to compare the prevalence of different gene
polymorphic forms in patients with cancer to the same
gene polymorphism of normal unaffected control individ-
uals [32].
Polymorphisms of gene variants that are involved in
carcinogenesis are the most studied particularly those
modifying the bioavailability, metabolism, afﬁnity, and
activity of several dietary constituents. Moreover, genes
that have a role in inﬂuencing other mechanisms of car-repair as well as those involved in the production of sex
hormones, have also been studied (Table 2) [39].
Genes involved in carcinogenesis are called candidate
genes or susceptibility genes. The candidate gene is deﬁned
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Table 3
Examples of types of reaction and enzymes that participate in xenobiotic
metabolism Quoted from (Brand et al. [42]).
Phase I reactions
Oxidation Ester hydrolysis
Xanthine oxidase Carboxylesterase
Peroxidase Amidases
Amine oxidase Alcohol dehydrogenase
Monoamine oxidase Aldehyde dehydrogenase
Dioxygenase Superoxide dismutase
Reduction
Cytochrome P450 dependent
reductase
Ketoreductase
Glutathione peroxidase
Hydration
Epoxide hydrolase
Phase II reactions
Glucuronosyltransferase Methylation
Sulfotransferase O-Methyl transferase
Glutathione S transferase N-Methyl transferase
Glucosyltransferase S-Methyl transferase
Thiotransferase Acetylation
Amide synthesis (transacylase) N-acetyl transferaseAcyltransferase
Thiosulfate sulfutransferase
as the gene that is located in a chromosome region pro-
posed of being involved in the expression in such disease.
A candidate gene can also be identiﬁed by its association
with its own speciﬁc phenotype and by linkage analysis to
a speciﬁc region of the genome [40].
2.3.1. Carcinogen metabolism genes
The biotransformation and/or detoxiﬁcation of a foreign
compound or carcinogen is performed by Phase I and Phase
II xenobiotic metabolizing enzymes. The aim of this process
is to convert toxic, water insoluble, and not easily exc-
retable compounds to compounds which are water soluble
and more easily excreted. This is performed by conjugating
the product of Phase I reaction to a carrier that facilitates
their excretion in urine or bile. Phase I enzymes are respon-
sible for the addition of one or more hydroxyl groups to the
molecules, converting it into hydrophilic polar intermedi-
ates that can bind to a speciﬁc conjugating substrate that
may  enhance its reactivity to be complexed with DNA or
protein. Sometimes this binding to DNA may  produce car-
cinogens through enhancing the promutagenesis process
[41].
The enzymes of Phase I reaction are cytochromes P450
that are coded by CYP gene family. Phase II or conjugating
enzymes remove the polar intermediates from the body
via their coupling to conjugating compounds such as glu-
tathione, glutamine, and others. Several families of Phase
II metabolizing enzymes had been recorded. They include
glutathione-S-transferases, N-acetyltransferases, and UDP-
glucoronosyl-transferases. Polymorphisms of the genes of
Phase I and II enzymes may  increase or decrease the pos-
sibility of cancer risk relying on the speciﬁc enzymatic
activity that is being stimulated or inhibited as well as the
substrate involved (Table 3) [41].
Cytochrome P450 is a family of enzymes that cat-
alyze the oxidative transormation of several endogenous
and exogenous substances as they are known to be and Ultrastructure 4 (2016) 115–122
monoxygenases or hydroxylases enzymes. They are
expressed at different rates according to their tissue distri-
bution. Therefore, these enzymes are important to explain
the genetic susceptibility, carcinogen metabolism, and
metabolism of chemopreventive agents [41].
2.3.2. Steroid hormone metabolism genes
Estrogens promote breast carcinogenesis through acti-
vation of genes involved in the modiﬁcation of cell growth
and proliferation. Estrogen biosynthesis and metabolism is
a complex process and controlled by distinct and indepen-
dent genetic variations. The genetic variation of the genes
that are involved in the synthesis pathway of estrogens
may  alter their production. Genes in this pathway include
CYP17 and CYP19.  The bioavailability, half-life, and activ-
ity of estrogens are also inﬂuenced by other metabolizing
enzymes such as catechol-O-methyltransferase enzyme
(COMT) as it is involved in its biotransformation [42].
A 1931T-C polymorphism in the promoter region
of CYP17 gene has been studied and characterized.
CYP17 catalyzes the conversion of pregnolone to 17-
hydroxypregnolone. The homozygous variant for this gene
has a frequency rate of nearly 13% in the general popula-
tion. Some studies have linked the increased risk of breast
cancer with some CYP17 polymorphic forms [43].
COMT enzyme is a member of Phase II metabolizing
enzymes that are involved in the inactivation of catechol
estrogen molecules by conjugation with methyl group.
Some polymorphisms of the COMT gene are associated
with an amino acid substitution (Val158Met). This change
is associated with diminished methylation process and
consequently higher levels of estrogens. Many studies con-
ﬁrmed the higher incidence and prevalence of breast cancer
in women  who  have COMT Val158Met polymorphism
[44,45].
2.3.3. DNA repair genes
DNA repair corrects DNA damage induced endoge-
nously or exogenously. DNA repair genes protect the
genome from mutations. The capacity of DNA repair
systems to prevent mutation can be inﬂuenced by poly-
morphisms of their genes. Polymorphisms of those genes
are associated with altering their enzymatic activity and/or
the ability of the protein product to bind their protein or
receptor partner [45].
The best example of DNA repair mechanism is the X-
ray cross-complementing Group 1 protein (XRCC1). This is
involved in a mechanism called base excision mechanism.
Three genetic polymorphisms in the coding region of the
XRCC1 gene are speciﬁed at codons 194 (from Arg to Trp),
280 (from Arg to His), and 399 (from Arg to Gln). These
genetic polymorphisms code for changes in amino acids
that can change XRCC1 function [46].
Many studies have demonstrated that polymorphisms
at codons 194 and 399 of XRCC1 are associated with high
risk of developing of oropharyngeal squamous cell carci-
noma, especially in individuals who  are chronic users of
tobacco and alcohol. Also, it shows an association with colo-
rectal cancer among Egyptians, while, the variant 399Gln
has been reported to be associated with a lower skin can-
cers risk [44].
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The xeroderma pigmentosum group D (XPD) gene rep-
esents the genetic code of a DNA helicase enzyme that
s concerned with nucleotide excision repair mechanism.
ys751Gln and Asp312Asn genetic polymorphisms in the
PD gene have been documented. These two genetic poly-
orphic forms have been reported to be associated with
ecreased nucleotide excision repair capacity. Asp312 XPD
arriers were found to have nearly double the risk of
evelopment of lung cancer compared to noncarriers. By
ontrast, many studies have reported a relation between
NA damage (DNA adducts) and 751Gln XPD genotype
ven in apparently healthy individuals [47].
. Conclusion
The etiology and pathogenesis of cancer is a com-
lex interplay mechanism of genetic and environmental
actors. Dietary intake and nutrient supplements are con-
idered essential environmental factors, so scientists have
eported that dietary and nutrients could play an important
ole in cancer development. Moreover, many studies have
eported the intimate link of the quantity and quality of
ietary nutrients with cancer incidence and pathogenesis.
There is a marked variation in cancer development
ith the same dietary intake between individuals. This
ould be explained by the variation in their genetic
olymorphisms, which leads to the emerge of the con-
ept of nutrigenomics and nutrigenetics. Nutrigenomics
nd nutrigenetics may  explain the association of spe-
iﬁc nutrient intake with genetic variations on cancer
athogenesis. Nowadays, nutrigenomics is widely used
or discussing cancer development and pathogenesis or
ven the response to treatment as well as diet-related
r dependent diseases. Subsequently, nutrigenomics may
roceed in respect of the effective management of cancer
n an individualized nutritional consultation according to
he individuals’ genetic proﬁles.
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